FDA questions efficacy of testosterone and whether risks really do exist, page-16

Mita, tx for posting, great find!

This is a good article & clear from it that the journo both read the FDA broefing papers and actually spoke to some of the manufacturers, so this is leaps and bounds ahead of anything the oz journos did.
As we are still >20% off the pre papers release pricing, it gives cause to be bullish over the next few days, given both the sell-off and the likelihood of the FDA being "benign" in its conclusions.
In terms of influences on the share price, as I read it, the release of Q3 sales figures is likely to come out before the FDA issues anything definitive, so that is more likely price driver. Recent price action would suggest sales are going well.